Craig S. Gibbs
Chief Executive Officer at Asher Biotherapeutics, Inc.
Net worth: - $ as of 2024-03-30
Profile
Craig S.
Gibbs is currently the Chief Executive Officer at Asher Biotherapeutics, Inc. He previously worked as the Chief Business Officer at Forty Seven, Inc. from 2015 to 2020.
Gibbs was also a VP-Commercial Strategy, Planning & Operations at Gilead Sciences, Inc. from 1992 to 2013.
He served as an Independent Director at Tobira Therapeutics, Inc. from 2014 to 2016 and at Aridis Pharmaceuticals, Inc. from 2015 to 2023.
Gibbs holds a doctorate from the University of Glasgow, an MBA from Golden Gate University, and an undergraduate degree from Massey University.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2022-12-04 | 0 ( -.--% ) | - $ | 2024-03-30 |
Craig S. Gibbs active positions
| Companies | Position | Start |
|---|---|---|
Asher Biotherapeutics, Inc.
 Asher Biotherapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Asher Biotherapeutics, Inc. engages in the research and development of immunotherapy for cancer. The company was founded by Ivana Djuretic and Andy Yeung in 2019 and is headquartered in South San Francisco, CA. | Chief Executive Officer | 2020-08-31 |
Former positions of Craig S. Gibbs
| Companies | Position | End |
|---|---|---|
| ARIDIS PHARMACEUTICALS, INC. | Director/Board Member | 2023-03-26 |
| FORTY SEVEN, INC. | Corporate Officer/Principal | 2020-06-30 |
Tobira Therapeutics, Inc. /Old/
 Tobira Therapeutics, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Tobira Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, which focuses on developing and commercializing of therapies to treat liver disease, HIV, fibrosis and inflammation. Its lead product candidate, cenicriviroc or CVC, is a proprietary immunomodulator that may be used to treat a number of diseases, including NASH, kidney fibrosis, HIV-1 and others. The company was founded by Eckard Weber in September 2006 and is headquartered in South San Francisco, CA. | Director/Board Member | 2016-08-31 |
| GILEAD SCIENCES, INC. | Corporate Officer/Principal | 2012-12-31 |
Training of Craig S. Gibbs
| University of Glasgow | Doctorate Degree |
| Golden Gate University | Masters Business Admin |
| Massey University | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| GILEAD SCIENCES, INC. | Health Technology |
| Private companies | 4 |
|---|---|
Tobira Therapeutics, Inc. /Old/
Tobira Therapeutics, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Tobira Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, which focuses on developing and commercializing of therapies to treat liver disease, HIV, fibrosis and inflammation. Its lead product candidate, cenicriviroc or CVC, is a proprietary immunomodulator that may be used to treat a number of diseases, including NASH, kidney fibrosis, HIV-1 and others. The company was founded by Eckard Weber in September 2006 and is headquartered in South San Francisco, CA. | Health Technology |
Forty Seven, Inc.
 Forty Seven, Inc. Pharmaceuticals: MajorHealth Technology Forty Seven, Inc. develops therapies that target cancer immune evasion pathways. It develops Hu5F9-G4, a monoclonal antibody against human CD47 that potentially has applications spanning multiple tumor types and treatment modalities. The company was founded by Irving L. Weissman, Ravi Majeti, Mark Chao and Jens-Peter Volkmer in 2014 and is headquartered in Menlo Park, CA. | Health Technology |
Asher Biotherapeutics, Inc.
Asher Biotherapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Asher Biotherapeutics, Inc. engages in the research and development of immunotherapy for cancer. The company was founded by Ivana Djuretic and Andy Yeung in 2019 and is headquartered in South San Francisco, CA. | Commercial Services |
| Aridis Pharmaceuticals, Inc. |
- Stock Market
- Insiders
- Craig S. Gibbs
